Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brawley, O. W.
Right arrow Articles by Andriole, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Brawley, O. W.
Right arrow Articles by Andriole, G.

Chemoprevention of Prostate Cancer

Otis W. Brawley, MD, Scott Lucia, MD, and Gerald Andriole, MD

From the Department of Hematology and Oncology, Emory University, and The American Cancer Society, Atlanta, GA (OWB); University of Colorado, Denver, CO (SL); and Washington University, St. Louis, MO (GA)

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests Otis W. Brawley, MD, Chief Medical Officer, American Cancer Society, 250 Williams Street, NW, Atlanta, GA 30303-1002; e-mail: otis.brawley{at}cancer.org

Overview: Prostate cancer is a major health problem in the Western world. A drug that reduces incidence of the disease could have significant impact. Such a drug must be of low toxicity, and other benefits (e.g., prevention of benign prostatic hyperplasia [BPH] symptoms) would be desirable. 5-alpha reductase (5-AR) inhibitors are likely candidates. Data from clinical trials are reviewed.